Gain Therapeutics appoints Gene Mack as permanent CEO, Fuggetta as Principal Financial Officer

Gain Therapeutics, Inc.

Gene Mack, interim CEO since June 2024, appointed President and CEO and Board member effective Jan 6, 2025.
Mack resigns as CFO; receives $500K base salary, 50% target bonus, and option for 271,325 shares at $2.44.
Gianluca Fuggetta, VP of Finance, becomes SVP Finance and Principal Financial Officer; base salary CHF 200K.
Mack brings 25+ years biotech experience; Fuggetta previously served as interim Principal Financial Officer in 2024.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Gene Mack

President and Chief Executive Officer

GANX · Gain Therapeutics, Inc.

Effective: 2025-01-06
Filed: January 7, 2025, 6:59 PM ET

announced that Gene Mack has been appointed the Company’s President and Chief Executive Officer and a member of the Company’s board of directors (the “Board of Directors”), effective January 6, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gene Mack was appointed as President and Chief Executive Officer at Gain Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

announced that Gene Mack has been appointed the Company’s President and Chief Executive Officer and a member of the Company’s board of directors (the “Board of Directors”), effective January 6, 2025.

View on SEC.gov

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-001711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.